harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
Company profile
Ticker
HROW, HROWL, HROWM
Exchange
Website
CEO
Mark L. Baum
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bywater Resources, Inc, HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., TRANSDEL PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
ImprimisRx, LLC • Imprimis NJOF, LLC • ImprimisRx NJ, LLC • Harrow Eye, LLC • Harrow IP, LLC • ImprimisRx Nashville, LLC • Harrow Analytical Services, LLC ...
IRS number
450567010
HROW stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Harrow Announces First Quarter 2024 Financial Results
13 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
21 Mar 24
8-K
Other Events
20 Mar 24
8-K
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Harrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products
15 Feb 24
8-K
Harrow Announces New Appointments to its Board of Directors
29 Jan 24
Transcripts
HROW
Earnings call transcript
2024 Q1
14 May 24
HROW
Earnings call transcript
2023 Q4
20 Mar 24
HROW
Earnings call transcript
2023 Q3
13 Nov 23
HROW
Earnings call transcript
2023 Q2
9 Aug 23
HROW
Earnings call transcript
2023 Q2
9 Aug 23
HROW
Earnings call transcript
2023 Q1
11 May 23
HROW
Earnings call transcript
2022 Q4
23 Mar 23
HROW
Earnings call transcript
2022 Q3
14 Nov 22
HROW
Earnings call transcript
2022 Q2
14 Aug 22
HROW
Earnings call transcript
2022 Q1
9 May 22
Latest ownership filings
SC 13D/A
Eton Pharmaceuticals, Inc.
30 Apr 24
4
Change in insider ownership
25 Apr 24
4
Change in insider ownership
24 Apr 24
4
Change in insider ownership
19 Apr 24
4
Change in insider ownership
28 Mar 24
4
MARK L BAUM
25 Mar 24
4
Change in insider ownership
22 Mar 24
4
JOHN P. SAHAREK
6 Mar 24
4
JOHN P. SAHAREK
21 Feb 24
4
ANDREW R. BOLL
21 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.54 mm | 68.54 mm | 68.54 mm | 68.54 mm | 68.54 mm | 68.54 mm |
Cash burn (monthly) | 1.85 mm | (no burn) | 4.52 mm | 2.53 mm | 1.54 mm | (no burn) |
Cash used (since last report) | 4.01 mm | n/a | 9.80 mm | 5.48 mm | 3.34 mm | n/a |
Cash remaining | 64.53 mm | n/a | 58.74 mm | 63.06 mm | 65.20 mm | n/a |
Runway (months of cash) | 34.9 | n/a | 13.0 | 24.9 | 42.3 | n/a |
Institutional ownership, Q1 2024
62.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 110 |
Opened positions | 48 |
Closed positions | 14 |
Increased positions | 24 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 259.81 bn |
Total shares | 22.16 mm |
Total puts | 366.00 k |
Total calls | 112.60 k |
Total put/call ratio | 3.3 |
Largest owners | Shares | Value |
---|---|---|
Opaleye Management | 3.92 mm | $51.87 bn |
Private Capital Management | 3.01 mm | $39.85 bn |
BLK Blackrock | 2.18 mm | $28.88 bn |
Kaufman Daniel Louis | 1.89 mm | $15.27 mm |
Vanguard | 1.83 mm | $24.21 bn |
MS Morgan Stanley | 952.52 k | $12.60 bn |
Geode Capital Management | 693.98 k | $9.18 bn |
STT State Street | 635.37 k | $8.41 bn |
SF Stifel Financial | 520.79 k | $6.89 bn |
Deutsche Bank AG - Registered Shares | 501.02 k | $6.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Apr 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 9.97 | 20,000 | 199.40 k | 3,815,000 |
24 Apr 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 10.15 | 8,285 | 84.09 k | 3,795,000 |
23 Apr 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 10.29 | 11,715 | 120.55 k | 3,786,715 |
19 Apr 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 10.5575 | 29,400 | 310.39 k | 3,775,000 |
28 Mar 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 12.82 | 50,000 | 641.00 k | 3,745,600 |
22 Mar 24 | Baum Mark L | Common stock | Buy | Acquire P | No | No | 11.59 | 9,000 | 104.31 k | 2,137,525 |
News
Lake Street Maintains Buy on Harrow, Raises Price Target to $25
3 Jun 24
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $26
15 May 24
B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $29
15 May 24
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
14 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
14 May 24
Press releases
Harrow to Present at Two Investor Conferences in May
15 May 24
Harrow Announces First Quarter 2024 Financial Results
13 May 24
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
13 May 24
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
25 Apr 24
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
2 Apr 24